Therapeutic Drug Monitoring

Skip Navigation LinksHome > April 2010 - Volume 32 - Issue 2 > The Benefit of Simplification From Tipranavir/Ritonavir 500/...
Text sizing:
Therapeutic Drug Monitoring:
doi: 10.1097/FTD.0b013e3181d3f97f
Short Communication

The Benefit of Simplification From Tipranavir/Ritonavir 500/200 bid to 500/100 bid Guided by Therapeutic Drug Monitoring

Morello, Judit PharmD*; Rodríguez-Novoa, Sonia PhD*; Blanco, Francisco PhD*; Vispo, Eugenia PhD†; Barreiro, Pablo PhD†; Gonzalez-Pardo, Gema*; Jiménez-Nácher, Inmaculada PhD*; González-Lahoz, Juan PhD†; Soriano, Vincent PhD†

Collapse Box


Despite being among the most potent protease inhibitors, the use of tipranavir (TPV) is hampered by a high pill burden and frequent side effects compared with other boosted protease inhibitors. A total of 10 patients receiving TPV/ritonavir (TPV/RTV) 500/200 for longer than 6 months were randomized to stay on the same dosing schedule or switch to TPV/RTV 500/100. Although all patients on TVP/RTV 500/200 remained stable for the next 12 weeks, 3 out of 5 patients who switched doses experienced benefits in terms of reducing aminotransferases and total cholesterol. Fasting triglycerides were also reduced in 2 of them. Plasma HIV-RNA remained undetectable in all patients, despite the observed decline in TPV trough concentrations.

© 2010 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.